Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1232 • ACR Convergence 2024
Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Elizabeth Luce¹, Beth schneider² and Dianna cronin², ¹MyHealthTeam, San Francisco, CA, ²MyHealthTeams, San Francisco, CA
Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to…
Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
A. Francesca Setiadi¹, Maggie Burhans², Xuguang Hu², Stephen Colgan³, Kim Notari², Marcia C. Teixeira dos Santos², Apostolos Kontzias², Sue Cheng² and Nehal Mehta⁴, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Halton Hills, ON, Canada, ⁴The George Washington University School of Medicine, Washington, DC
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
Abstract Number: 1709 • ACR Convergence 2024
Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Liqun Diao², Joan Wither³, Igor Jurisica⁴, Vinod Chandran⁵ and Lihi Eder⁶, ¹Women's College Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) affects males and females equally, but differences exist in the clinical presentation and treatment response. The biological mechanisms driving these differences…
Abstract Number: 2312 • ACR Convergence 2024
National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
Dilli Poudel¹, Rashmi Dhital² and Paras Karmacharya³, ¹Vanderbilt University, Nashville, TN, Brentwood, TN, ²UC San Diego, Brentwood, TN, ³Vanderbilt University, Nashville, TN, Hermitage, TN
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease which significantly impacts quality of life and healthcare costs. However, true US population-level prevalence data is…
Abstract Number: 2329 • ACR Convergence 2024
Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
Gretchen Ball¹, Hassan Hamade², Sarah Romanelli², Melissa Zundell², Sangyoon Shin², Thami Senthilkumaran², Angela Lamb², Saakshi Khattri³, Lourdes Perez Chada⁴, Joseph Merola⁵ and Alice Gottlieb⁶, ¹Albert Einstein College of Medicine, Ridgefield, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Mount Sinai Medical Center, New York, NY, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Newton, MA, ⁶Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is frequently undiagnosed and/or undertreated. Given the elevated risk of disability with treatment delays, we launched a quality improvement initiative to…
Abstract Number: 2349 • ACR Convergence 2024
Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
Abigail Cave¹, Sheng Han Li², Nikita Looby³, Max Kotiyar⁴, Igor Jurisica⁵, Vathany Kulasingam⁶, Proton Rahman⁷ and Vinod Chandran⁸, ¹Dalhousie University, Alliston, ON, Canada, ²Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, ³Psoriatic Arthritis Program Schroeder Arthritis Institute, Toronto, Canada, ⁴Data Science Discovery Centre for Chronic Dsiease, Krembil Research Institute, Toronto, Canada, ⁵Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁶Laboratory Medicine Program, Unviersity Health Network, Toronto, Canada, ⁷Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: There is an unmet need to improve treatments for patients with Psoriatic Arthritis (PsA). Biologic disease-modifying antirheumatic drugs (bDMARDs) such as interleukin-17 inhibitors (IL-17i)…
Abstract Number: 2582 • ACR Convergence 2024
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Iain McInnes¹, Laura Coates², Philip Mease³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Lihi Eder⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Eva Cullen⁹, Kristian Reich⁹, Christopher Ritchlin¹⁰ and Joseph F. Merola¹¹, ¹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵University of California San Diego, La Jolla, CA, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…
Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 0772 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Suzanne D. Khalili¹, Daniel Aletaha³ and Josef Smolen⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1464 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, Mitsumasa Kishimoto⁴, Ennio Lubrano⁵, Proton Rahman⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Minni Koivunen⁹, Frederic Lavie¹⁰, Enrique R. Soriano¹¹, Ruben Queiro Silva¹², Frank Behrens¹³ and Stefan Siebert¹⁴, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁵Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁶Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, ⁹Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, ¹⁰Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹³University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ¹⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…
Abstract Number: 1711 • ACR Convergence 2024
Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
Sreemoyee Ghosh¹, Chiara Pastrello², Omar F. Cruz-Correa³, Darshini Ganatra⁴, Katerina Oikonomopoulou³, Melanie Anderson⁵, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Institute of Medical Science, University of Toronto and Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis (Pso) is a chronic immune mediated inflammatory skin disease. Up to 24% of Pso patients develop psoriatic arthritis (PsA). Pathophysiology of PsA is…
Abstract Number: 2313 • ACR Convergence 2024
Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
Christine Loftis¹, Liron Caplan², Joanna Padilla Zepeda³, Nicole Mukooba³, Mayan Caplan³, Meika Fang⁴, Liya Stolyar⁵, Jessica Walsh⁶, Gail Kerr⁷, Siba Raychaudhuri⁸, Andreas Reimold⁹ and Maida Wong¹⁰, ¹University of Colorado Anschutz School of Medicine, Aurora, CO, ²Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ³University of Colorado, Aurora, CO, ⁴Veterans Affairs, Los Angeles, ⁵Veterans Affairs, Palo Alto, ⁶Veterans Affairs, Salt Lake City, UT, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Veterans Affairs, Sacramento, ⁹University of Texas Southwestern Medical School, Dallas, ¹⁰Veterans Affairs, Long Beach
Background/Purpose: Studies have suggested a delay between symptom onset and diagnosis for Psoriatic Arthritis (PsA) and axial spondyloarthritis (axSpA). Factors that influence this delay have…
Abstract Number: 2330 • ACR Convergence 2024
Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
Rebecca haberman¹, Seungha Um², Catherine Howe³, Kyra Chen², Brianna Fu², Adamary Felipe², Stephanie Eichman², Margaret Coyle⁴, Eileen Lydon⁵, Andrea Neimann², Soumya Reddy⁶, Samrachana Adhikari² and Jose Scher⁷, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, NYC, ³New York University Langone Medical Center, New York, NY, ⁴NYU Langone, Brooklyn, NY, ⁵NYU, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in therapeutics over the past two decades, psoriatic arthritis (PsA) remains difficult to treat, with joint outcomes lagging far behind those…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].